专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08703411B2 Cryopreservation of umbilical cord tissue for cord tissue-derived stem cells 有权
标题翻译：用于脐带组织来源的干细胞的脐带组织的冷冻保存
公开(公告)号：US08703411B2
公开(公告)日：2014-04-22
申请号：US13245145
申请日：2011-09-26
申请人： Hsiu-Kang Chang , Wei-Yu Lo
发明人： Hsiu-Kang Chang , Wei-Yu Lo
IPC分类号： A01N1/02 , C12N5/073
CPC分类号： C12N5/0605 , A01N1/0221 , C12N5/0665
摘要： A method of preserving an umbilical cord is disclosed. The method comprises obtaining a segment of an umbilical cord; mincing the segment of the umbilical cord into cord tissue pieces; admixing the cord tissue pieces with a cryogenic composition comprising a cryoprotectant and a protein to form a mixture; shaking the mixture for a duration of no shorter than 20 minutes and no longer than 40 minutes; and cryopreserving the mixture.
摘要翻译：公开了一种保留脐带的方法。该方法包括获得脐带的一段; 将脐带的切片切成脐带组织片; 用包含冷冻保护剂和蛋白质的低温组合物混合脐带组件以形成混合物; 摇动混合物持续时间不少于20分钟，不超过40分钟; 并冷冻保存混合物。

2. 发明授权

US07595054B2 Fusion antigen used as vaccine 有权
标题翻译：融合抗原用作疫苗
公开(公告)号：US07595054B2
公开(公告)日：2009-09-29
申请号：US11948327
申请日：2007-11-30
申请人： Chao-Wei Liao , Chung-Nan Weng , Hsiu-Kang Chang
发明人： Chao-Wei Liao , Chung-Nan Weng , Hsiu-Kang Chang
IPC分类号： A61K39/00 , A61K39/155
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/552 , A61K2039/55566 , A61K2039/57 , A61K2039/6031 , C07K14/21 , C07K2319/01 , C07K2319/04 , C07K2319/70 , C12N2770/10022 , C12N2770/10034
摘要： Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.
摘要翻译：融合抗原用作疫苗。本发明涉及对靶细胞特异性的融合抗原。融合抗原含有配体部分，假单胞菌外毒素A易位结构域II，抗原部分和羧基末端部分。配体部分能够反应，识别或结合靶细胞上的受体。羧基末端部分允许在靶细胞的内质网（ER）膜中保留和加工融合抗原。还公开了使用其诱导免疫应答的药物组合物和方法。

3. 发明授权

US07129619B2 Ultrasonic nebulizer for producing high-volume sub-micron droplets 有权
标题翻译：用于生产高体积亚微米液滴的超声雾化器
公开(公告)号：US07129619B2
公开(公告)日：2006-10-31
申请号：US10617796
申请日：2003-07-14
申请人： Che-Hua Yang , Hsiu-Kang Chang , Tiao-Ling Hsieh , Kun-Yi Tsai
发明人： Che-Hua Yang , Hsiu-Kang Chang , Tiao-Ling Hsieh , Kun-Yi Tsai
IPC分类号： H01L41/04
CPC分类号： B05B17/0607
摘要： An ultrasonic nebulizer for producing high-volume sub-micron droplets is disclosed. The ultrasonic nebulizer utilizes a 3 or 5 MHz frequency as an oscillation frequency for producing sub-micron droplets. The nebulizer can also use at least one piezoelectric ceramic oscillator for increasing the volume of the droplets. The ultrasonic nebulizer comprises an ac/dc converter, an oscillator circuit, an amplifying device, a nebulization chamber, and at least one piezoelectric ceramic oscillator. The ac/dc converter rectifies an ac current to a dc current. The oscillator circuit produces an oscillation signal with a frequency larger than or equal to 3 MHz. The amplifying device amplifies the oscillation signal. The nebulization chamber has a lower face for holding a liquid to be nebulized. At least one piezoelectric ceramic oscillator is formed on the lower face of the nebulization chamber and connected to the amplified signal providing an ultrasonic output to cause nebulization for producing high-volume sub-micron droplets.
摘要翻译：公开了一种用于产生高体积亚微米液滴的超声雾化器。超声雾化器利用3或5MHz频率作为产生亚微米液滴的振荡频率。喷雾器还可以使用至少一个压电陶瓷振荡器来增加液滴的体积。超声雾化器包括一个ac / dc转换器，一个振荡器电路，一个放大装置，一个雾化室和至少一个压电陶瓷振荡器。交流/直流转换器将交流电流整流到直流电流。振荡电路产生频率大于或等于3MHz的振荡信号。放大装置放大振荡信号。雾化室具有用于保持要雾化的液体的下表面。在雾化室的下表面上形成至少一个压电陶瓷振荡器，并连接到放大信号，提供超声波输出以产生雾化以产生高体积亚微米液滴。

4. 发明授权

US08771705B2 Combination of protein vaccine and mesenchymal stem cells for treating cancer 有权
标题翻译：蛋白质疫苗和间充质干细胞的组合用于治疗癌症
公开(公告)号：US08771705B2
公开(公告)日：2014-07-08
申请号：US12844044
申请日：2010-07-27
申请人： Win-Ping Deng , Hsiu-Kang Chang , Hung-Chien Wei , Tsang-Hsien Alexander Wu
发明人： Win-Ping Deng , Hsiu-Kang Chang , Hung-Chien Wei , Tsang-Hsien Alexander Wu
IPC分类号： A61K39/12 , A61K35/12 , A61K39/00
CPC分类号： A61K39/0011 , A61K2035/124 , A61K2039/5156 , A61K2039/5158 , A61K2039/545 , A61K2039/6037 , C12N2710/20022
摘要： A method for inhibiting growth and/or metastasis of a tumor in a mammal is disclosed. The method comprises administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation; and administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein, and thereby inhibiting growth and/or metastasis of a tumor in the mammal. A therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal is also disclosed.
摘要翻译：公开了抑制哺乳动物肿瘤生长和/或转移的方法。所述方法包括向有需要的哺乳动物施用有效量的包含编码至少一种致癌蛋白的转基因的干细胞，其中所述干细胞是永生的并且不显示肿瘤转化的迹象; 以及向所述哺乳动物施用疫苗组合物，所述疫苗组合物包含有效量的至少一种免疫原性蛋白质，所述免疫原性蛋白质能够引发至少一种对所述至少一种致癌蛋白质特异性的抗体，从而抑制所述哺乳动物肿瘤的生长和/或转移。还公开了用于抑制哺乳动物肿瘤生长和/或转移的治疗试剂盒。

5. 发明授权

US08206950B2 Fusion antigen used as vaccine and method of making them 有权
标题翻译：用作疫苗的融合抗原及其制备方法
公开(公告)号：US08206950B2
公开(公告)日：2012-06-26
申请号：US12276334
申请日：2008-11-22
申请人： Chao-Wei Liao , Chung-Nan Weng , Hsiu-Kang Chang
发明人： Chao-Wei Liao , Chung-Nan Weng , Hsiu-Kang Chang
IPC分类号： C12P21/00 , A61K39/104 , A61K39/12
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/57 , C07K14/21 , C07K2319/01 , C07K2319/04 , C07K2319/70 , C12N2760/16122 , C12N2760/16134 , C12N2770/10022 , C12N2770/10034
摘要： Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.
摘要翻译：用作疫苗的融合抗原及其制备方法。该方法包括：（1）选择含有至少一个表位的病毒蛋白序列片段; （2）设计编码病毒蛋白的选定区段的DNA片段; （3）将DNA片段插入假单胞菌外毒素A（PE）载体中以获得嵌合基因质粒，并在宿主细胞中表达嵌合基因质粒以获得嵌合疫苗病毒抗原。 PE载体含有PE片段，其具有结合结构域和易位结构域，以及包含内质网保留序列的羧基末端部分。将编码病毒蛋白质的所选区段的DNA片段插入PE片段和羧基末端部分之间。

6. 发明授权

US07465455B2 Fusion protein of porcine reproductive and respiratory syndrome virus as PRRS vaccine 有权
标题翻译：猪繁殖与呼吸综合征病毒融合蛋白作为PRRS疫苗
公开(公告)号：US07465455B2
公开(公告)日：2008-12-16
申请号：US11480387
申请日：2006-07-05
申请人： Hsiu-Kang Chang , Chao-Wei Liao
发明人： Hsiu-Kang Chang , Chao-Wei Liao
IPC分类号： A61K39/12
CPC分类号： C07K14/21 , A61K39/12 , A61K39/385 , A61K2039/552 , A61K2039/55566 , A61K2039/6037 , C07K14/005 , C07K2319/02 , C07K2319/04 , C12N2770/10022 , C12N2770/10034
摘要： A fusion protein of porcine reproductive and respiratory syndrome virus (PRRSV) for PRRSV vaccine. The fusion protein includes: (a) a Pseudomoitas Exoloxin A (PE) peptide that comprises a binding domain and a translocating domain; (b) a peptide fragment that contains a N-terminal portion of PRRSV ORF6 protein; (c) a peptide fragment that has a N-terminal portion of PRRSV ORF5 protein; and (d) a carboxyl terminal domain that comprises an amino acid seciuence KDEL. The PE peptide is located at the N-terminus of the fusion protein, and the peptide fraament containinC the N-terminal portion of PRRSV ORF5 protein is located between the peptide fragment containing the N-terminal portion of PRRSV ORF6 protein and the carboxyl terminal domain.
摘要翻译：猪繁殖与呼吸综合征病毒（PRRSV）融合蛋白用于PRRSV疫苗。融合蛋白包括：（a）包含结合结构域和易位结构域的假单胞菌素外切酶A（PE）肽; （b）含有PRRSV ORF6蛋白的N末端部分的肽片段; （c）具有PRRSV ORF5蛋白的N末端部分的肽片段; 和（d）包含氨基酸定序KDEL的羧基末端结构域。 PE肽位于融合蛋白的N末端，并且包含PRRSV ORF5蛋白的N末端部分的肽花丝位于包含PRRSV ORF6蛋白的N末端部分的肽片段和羧基末端结构域。

7. 发明申请

US20080206271A1 FUSION ANTIGEN USED AS VACCINE 有权
标题翻译：作为疫苗使用的融合抗原
公开(公告)号：US20080206271A1
公开(公告)日：2008-08-28
申请号：US11948327
申请日：2007-11-30
申请人： Chao-Wei Liao , Chung-Nan Weng , Hsiu-Kang Chang
发明人： Chao-Wei Liao , Chung-Nan Weng , Hsiu-Kang Chang
IPC分类号： A61K39/00 , C07K2/00 , A61P37/04 , C07K14/00
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/552 , A61K2039/55566 , A61K2039/57 , A61K2039/6031 , C07K14/21 , C07K2319/01 , C07K2319/04 , C07K2319/70 , C12N2770/10022 , C12N2770/10034
摘要： Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.
摘要翻译：融合抗原用作疫苗。本发明涉及对靶细胞特异性的融合抗原。融合抗原含有配体部分，假单胞菌外毒素A易位结构域II，抗原部分和羧基末端部分。配体部分能够反应，识别或结合靶细胞上的受体。羧基末端部分允许在靶细胞的内质网（ER）膜中保留和加工融合抗原。还公开了使用其诱导免疫应答的药物组合物和方法。

8. 发明申请

US20070243587A1 Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus 审中-公开
标题翻译：使用反向遗传工程平台生产禽流感病毒蛋白疫苗和蛋白疫苗
公开(公告)号：US20070243587A1
公开(公告)日：2007-10-18
申请号：US11783300
申请日：2007-04-09
申请人： Chao-We Liao , Hsiu-Kang Chang , KinKai Hwang
发明人： Chao-We Liao , Hsiu-Kang Chang , KinKai Hwang
IPC分类号： C12P21/06 , C12N15/86 , C12N7/02 , C07H21/04 , C07K14/08
CPC分类号： A61K39/145 , A61K39/12 , C07K14/005 , C07K2319/55 , C12N7/00 , C12N2760/16122 , C12N2760/16134 , C12N2760/16151
摘要： The present invention relates to a preparation method of protein vaccines, and comprises the steps of: (a) providing at least one amino acid sequence of an epitope of a target antigen protein; (b) converting the amino acid sequence into a nucleic acid sequence and modifying the codons; (c) synthesising a plurality of primers of the modified nucleic acid sequence; (d) synthesising the modified nucleic acid sequence in vitro; (e) inserting the synthesized fragment of the modified nucleic acid sequence into a plasmid; (f) transforming the plasmid into a host cell to produce the modified nucleic acid encoded epitope peptide; and (g) collecting and purifying the produced peptide.
摘要翻译：本发明涉及蛋白疫苗的制备方法，包括以下步骤：（a）提供靶抗原蛋白表位的至少一个氨基酸序列; （b）将氨基酸序列转化为核酸序列并修饰密码子; （c）合成修饰的核酸序列的多个引物; （d）体外合成修饰的核酸序列; （e）将经修饰的核酸序列的合成片段插入质粒; （f）将质粒转化到宿主细胞中以产生经修饰的核酸编码的表位肽; 和（g）收集和纯化产生的肽。

9. 发明申请

US20060039919A1 Fusion protein for inhibiting cervical cancer 有权
标题翻译：用于抑制宫颈癌的融合蛋白
公开(公告)号：US20060039919A1
公开(公告)日：2006-02-23
申请号：US11206138
申请日：2005-08-18
申请人： Hsiu-Kang Chang , Chao-We Liao , Wen-Fang Cheng
发明人： Hsiu-Kang Chang , Chao-We Liao , Wen-Fang Cheng
IPC分类号： C07K14/025 , C07H21/04 , C12P21/04 , A61K39/12
CPC分类号： C07K14/005 , A01K2267/0331 , A61K38/00 , A61K39/00 , C07K2319/01 , C07K2319/04 , C12N2710/20022
摘要： A fusion protein for inhibiting cervical cancer is disclosed, which comprises a peptide sequence of human papillomavirus type 16, a peptide translocating peptide for translocation, and a peptide within a carboxyl terminal fragment. The present invention further comprising a composition of antibody, which conjugates to E7 peptide, wherein the nucleotide sequence corresponding to the amino acid sequence of the E7 peptide is shown as SEQ. ID. NO.1.
摘要翻译：公开了一种用于抑制宫颈癌的融合蛋白，其包含人乳头状瘤病毒16型的肽序列，用于易位的肽易位肽和羧基末端片段中的肽。本发明还包含与E7肽结合的抗体组合物，其中对应于E7肽的氨基酸序列的核苷酸序列显示为SEQ ID NO： ID。 NO.1。

10. 发明授权

US08372407B2 Chimeric HIV fusion proteins as vaccines 有权
标题翻译：嵌合HIV融合蛋白作为疫苗
公开(公告)号：US08372407B2
公开(公告)日：2013-02-12
申请号：US13452358
申请日：2012-04-20
申请人： Chao-Wei Liao , Hsiu-Kang Chang
发明人： Chao-Wei Liao , Hsiu-Kang Chang
IPC分类号： A61K39/21 , A61K39/295
CPC分类号： C07K14/21 , A61K39/12 , A61K39/21 , A61K2039/5254 , A61K2039/54 , A61K2039/545 , A61K2039/55566 , A61K2039/57 , C07K14/005 , C07K2319/00 , C07K2319/10 , C07K2319/40 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： A method for inducing HIV antigen-specific immune responses is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of a chimeric fusion protein comprising: (a) a first polypeptidyl region comprising a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain, located at the N-terminus of the fusion protein; and (b) a second polypeptidyl region with a fusion peptide of HIV gp120-C1-C5-gp41 with the amino acid sequence of SEQ ID NO: 7. A method for inducing neutralizing antibodies against HIV-1 is also disclosed.
摘要翻译：公开了诱导HIV抗原特异性免疫应答的方法。所述方法包括向有需要的受试者施用治疗有效量的嵌合融合蛋白，其包含：（a）包含位于N末端的假单胞菌素外毒素A（PE）结合结构域和PE易位结构域的第一多肽基区的融合蛋白; 和（b）具有HIV gp120-C1-C5-gp41的融合肽与SEQ ID NO：7的氨基酸序列的第二多肽基区域。还公开了诱导针对HIV-1的中和抗体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式